{
    "nctId": "NCT04785521",
    "briefTitle": "Glutamate Excitotoxicity in Brain Metastases From Lung, Breast and Melanoma Treated With Stereotactic Radiosurgery",
    "officialTitle": "Glutamate Excitotoxicity in Brain Metastases From Lung, Breast and Melanoma Treated With Stereotactic Radiosurgery",
    "overallStatus": "RECRUITING",
    "conditions": "Brain Metastases, Adult",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 100,
    "primaryOutcomeMeasure": "Serum markers determination in newly diagnosed BM (lung, breast and melanoma) patients, before SRS treatment.",
    "eligibilityCriteria": "Inclusion Criteria (Target group)\n\n* Adult patients carrying melanoma, breast or lung cancer BM of new diagnosis\n* Patients eligible to SRS-GK treatment\n\nInclusion Criteria (Control group 1)\n\n- Adult patients carrying melanoma, breast or lung cancer without BM\n\nInclusion Criteria (Control group 2)\n\n* Adult patients carrying intracranial extra-axial benign tumor\n* Patients eligible to SRS-GK treatment\n\nExclusion Criteria:\n\n* Acute or chronic liver disease\n* Severe anemia (Hb \\<8g/dl)\n* Pregnant or breastfeeding patient\n* Pediatric patients\n* Patients not able to express informed consent",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}